6-APB (Benzofury): Complete Toxicology, Fatalities, 5-HT2B Risk & Dependence Monograph

6-APB (Benzofury): Complete Toxicology, Fatalities, 5-HT2B Risk & Dependence Monograph

Emergency entactogen/stimulant toxicity: Seizure, dangerous overheating, severe agitation/paranoia, chest pain, collapse, very fast or irregular heartbeat, severe muscle rigidity/clonus, or loss of consciousness after an unknown entactogen requires urgent medical care.

Quick answer

6-APB is 6-(2-aminopropyl)benzofuran, a benzofuran entactogen/stimulant often sold historically as “Benzofury.”

Its pharmacology combines:

• serotonin;
• dopamine;
• norepinephrine

transporter activity with potent serotonin-receptor signaling.

The human evidence includes:

• an analytically confirmed acute psychosis case;
• multiple fatal mixed-drug cases;
• a fatal 5-APB/6-APB case with extensive postmortem tissue analysis;
• direct human urinary detectability work.

The strongest chronic mechanistic concern is its potent 5-HT2B agonism, although the actual incidence of heart-valve disease in human 6-APB users has never been measured prospectively.

Identity

History

6-APB arose from medicinal-chemistry exploration of benzofuran analogues of MDA/amphetamine-like entactogens.

It entered European recreational markets around 2010–2011 and was commonly marketed under names such as:

• Benzofury;
• 6-APB;
• “legal ecstasy.”

The apparent legality of early products did not reflect a clinical safety program.

Human poisoning reports appeared soon afterward.

Relationship to 5-APB

5-APB and 6-APB:

• have the same formula;
• differ in the benzofuran substitution position;
• can produce similar mass spectra.

They are not analytically interchangeable.

Proper interpretation requires chromatographic or other validated positional-isomer separation.

Relationship to MDMA/MDA

6-APB shares important functional properties with MDMA/MDA:

• monoamine release/inhibition;
• serotonergic effects;
• sympathomimetic activation.

But it also has distinct receptor pharmacology.

No controlled human trial establishes a safe MDMA-equivalent dose.

Monoamine pharmacology

Benzofuran pharmacology studies show 6-APB interacts with:

• serotonin transporter;
• dopamine transporter;
• norepinephrine transporter.

The resulting increase in extracellular monoamines explains its entactogenic/stimulant profile.

Preclinical work found 5-APB/6-APB monoamine effects resembling MDA.

5-HT2B receptor agonism

One of the most important pharmacology findings is that both 5-APB and 6-APB are potent full agonists at 5-HT2B receptors.

Why that matters:

chronic stimulation of 5-HT2B receptors by some drugs has been linked with cardiac-valve pathology.

Evidence boundary

No longitudinal human 6-APB study establishes:

• incidence of valvulopathy;
• cumulative exposure threshold;
• reversibility;
• screening interval.

The receptor result is a serious mechanistic concern—not proof that every repeated user develops valve disease.

5-HT2A/2C and serotonergic effects

6-APB also interacts with other serotonin receptors.

These effects contribute to:

• perceptual changes;
• entactogenic effects;
• serotonergic toxicity risk.

No single receptor explains the full clinical syndrome.

Analytically confirmed acute psychosis

A 21-year-old man developed:

• severe agitation;
• paranoid thinking;
• self-injurious behavior

after using 6-APB purchased online.

Urine contained an estimated 2,000 ng/mL 6-APB.

Other findings included cannabis and JWH-122 metabolites.

The patient required benzodiazepine treatment and psychiatric admission.

Interpretation

The case confirms 6-APB exposure during severe psychosis/agitation.

Cannabis and synthetic-cannabinoid exposure limit the ability to attribute the entire syndrome to 6-APB alone.

Acute toxicity

Benzofuran stimulant/entactogen toxicity can include:

• tachycardia;
• hypertension;
• hyperthermia;
• agitation;
• anxiety;
• confusion;
• psychosis;
• seizures;
• clonus;
• reduced consciousness;
• cardiovascular collapse.

Clinical severity is influenced by:

• co-drugs;
• product identity;
• temperature/activity;
• individual vulnerability.

Serotonin toxicity

Because 6-APB strongly affects serotonergic systems, serotonin toxicity is plausible.

Severe features can include:

• agitation;
• hyperthermia;
• clonus/hyperreflexia;
• autonomic instability;
• altered mental status.

Not every severe benzofuran intoxication meets formal serotonin-syndrome criteria.

Hyperthermia and secondary organ injury

Extreme overheating can produce:

• rhabdomyolysis;
• kidney injury;
• metabolic abnormalities;
• cardiovascular collapse.

Club/festival settings can add:

• physical exertion;
• ambient heat;
• dehydration.

Fatality evidence

Mixed 5-IT/6-APB deaths

6-APB was found in several fatalities involving 5-IT and other stimulants/entactogens.

In one case, femoral 6-APB was approximately 0.2 mg/L with 5-IT.

The death was attributed to the drug combination.

This does not establish a 6-APB-only fatal threshold.

Fatal 5-APB + 6-APB case

A 2017 fatal intoxication later analyzed in detail had peripheral blood concentrations of approximately:

• 850 ng/mL 5-APB;
• 300 ng/mL 6-APB.

Researchers also examined:

• central blood;
• urine;
• bile;
• hair;
• multiple tissues.

This gives valuable distribution evidence while remaining a mixed-benzofuran death.

Postmortem and hair interpretation

The 2022 HPLC-MS/MS method can distinguish and quantify both isomers across several specimen types.

Hair can support repeated/past exposure.

It cannot establish:

• exact dose;
• acute impairment at a specific time.

Metabolism

Compared with N-methyl benzofurans, 6-APB is metabolized to a relatively limited extent.

An important metabolic pathway includes:

• oxidation/hydroxylation;
• benzofuran-ring transformation;
• ring opening;
• formation of a carboxylic-acid/hydroxy amphetamine metabolite.

The unchanged parent drug remains an important urine target.

Human urinary detectability

A human observational analytical study included healthy volunteers exposed to several NPS, including 6-APB.

For 6-APB, monitoring parent drug in urine was effective at the study reporting threshold.

This is useful for antidoping/toxicology detection.

It is not a controlled safety trial.

Drug testing

Routine immunoassays

Amphetamine-type screens may cross-react but cannot identify 6-APB specifically.

A generic positive is not proof of 6-APB.

A negative does not guarantee absence.

Definitive testing

Useful approaches include:

• HPLC-MS/MS;
• LC-HRMS;
• GC-MS with derivatization/retention-time separation;
• authentic standards.

5-APB vs 6-APB analytical separation

Routine liquid chromatography may not always separate these isomers adequately.

Published methods use:

• tailored chromatography;
• derivatized GC-MS;
• validated LC-MS/MS

to distinguish them.

Every concentration table should be checked for isomer certainty before reuse.

Interactions

No controlled 6-APB interaction trial defines safe combinations.

High-concern combinations include:

• other serotonergic entactogens/stimulants;
• MAO inhibitors;
• other sympathomimetics;
• alcohol/benzodiazepines;
• unknown multi-NPS products.

Mixed fatal cases demonstrate that benzofurans frequently appear alongside other psychoactive substances.

Tolerance

Repeated serotonergic stimulant exposure can produce tolerance.

No controlled 6-APB human tolerance study establishes:

• onset;
• magnitude;
• cross-tolerance with MDMA/5-APB.

Tolerance to desired effects does not guarantee protection from:

• hyperthermia;
• cardiac stress;
• serotonin toxicity;
• psychiatric harm.

Dependence and problematic use

6-APB-specific dependence epidemiology is limited.

Its dopamine/serotonin/norepinephrine pharmacology supports possible:

• craving;
• redosing;
• compulsive use;
• binge patterns.

The prevalence of stimulant use disorder among 6-APB users is not established.

Withdrawal / post-use symptoms

After repeated entactogen/stimulant use, possible symptoms include:

• fatigue;
• depressed mood;
• anhedonia;
• sleep disturbance;
• irritability;
• craving.

No validated 6-APB-specific withdrawal timeline exists.

Severe depression, suicidality or persistent psychosis warrants medical attention.

Treatment and support

There is no medication approved specifically for 6-APB use disorder.

Acute severe toxicity is treated according to complications such as:

• hyperthermia;
• agitation;
• seizure;
• cardiovascular instability;
• trauma.

For compulsive stimulant-like use, evidence-based stimulant-use-disorder treatment includes contingency management, often alongside CBT/community reinforcement.

Special populations

Controlled 6-APB safety data are inadequate for:

• pregnancy/breastfeeding;
• adolescents;
• cardiovascular disease;
• valvular heart disease;
• seizure disorders;
• bipolar/psychotic disorders;
• liver/kidney disease.

The 5-HT2B signal creates particular uncertainty for repeated exposure in people with cardiac disease.

Forensic interpretation

Concentration is not dose

Fatal and nonfatal values cannot be converted into dose estimates.

Mixed deaths require mixed causation analysis

6-APB often co-occurs with other benzofurans or stimulants.

Isomer identity matters

A “benzofuran” or unresolved APB result is not enough.

Legal status — dated October 3, 2026

United States

The federal schedules reviewed for this monograph do not list 6-APB by name as a separately scheduled controlled substance.

However, U.S. federal authorities have treated 6-APB as an analogue of MDMA in criminal casework.

Federal analogue-law application is fact-specific, including intended human consumption.

Many U.S. states independently control 6-APB.

International

UNODC tracks 6-APB as a stimulant phenethylamine NPS.

This review does not identify a UN convention scheduling decision specifically listing 6-APB.

Many countries separately control it under national or generic NPS legislation.

Myths and misconceptions

“6-APB is just legal MDMA.”
False legally and scientifically.

“5-HT2B agonism means every user will develop valve disease.”
No. It is a mechanistic concern with no human incidence estimate.

“The 300 ng/mL fatal case concentration is a lethal threshold.”
False. That death also contained 5-APB.

“5-APB and 6-APB are basically the same toxicology result.”
False. They are distinct positional isomers.

“No federal named listing means risk is low.”
False. Legal status and toxicology are separate questions.

Evidence ledger

Related evidence

• 5-APB
• 5-MAPB
• 6-MAPB
• Benzofurans & entactogens hub
• Substance Use, Dependence & Harm Reduction hub

Bottom line

6-APB has enough evidence to move well beyond a “Benzo Fury” encyclopedia stub.

The literature establishes potent monoamine and 5-HT2B pharmacology, analytically confirmed psychosis, fatal mixed exposures, and reliable isomer-specific toxicology methods.

The biggest long-term unknown is especially important: its receptor profile raises a plausible cardiac-valve concern, but no human cohort has measured that risk.

That is exactly the kind of uncertainty a masterclass page should make visible rather than replacing with forum folklore.